Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.35)
# 391
Out of 4,981 analysts
65
Total ratings
58.7%
Success rate
17.15%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $68.81 | +10.45% | 4 | Aug 7, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $10 → $14 | $13.08 | +7.03% | 5 | Aug 6, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $12.39 | +12.99% | 1 | Aug 4, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $33.12 | -6.40% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $13.35 | -32.58% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $25.72 | +28.30% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $113.74 | +67.05% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $84.00 | +19.05% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $21.13 | -10.08% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $299.04 | +30.42% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $85.13 | -35.39% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $54.79 | +0.38% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $125.63 | +27.36% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $474.46 | +41.21% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $7.31 | +173.60% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,260.13 | +11.10% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.20 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $32.07 | +180.64% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $188.54 | +43.21% | 4 | Dec 20, 2023 |
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $68.81
Upside: +10.45%
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Overweight
Price Target: $10 → $14
Current: $13.08
Upside: +7.03%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $12.39
Upside: +12.99%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $33.12
Upside: -6.40%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $13.35
Upside: -32.58%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $25.72
Upside: +28.30%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $113.74
Upside: +67.05%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $84.00
Upside: +19.05%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $21.13
Upside: -10.08%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $299.04
Upside: +30.42%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $85.13
Upside: -35.39%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $54.79
Upside: +0.38%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $125.63
Upside: +27.36%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $474.46
Upside: +41.21%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $7.31
Upside: +173.60%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,260.13
Upside: +11.10%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.20
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $32.07
Upside: +180.64%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $188.54
Upside: +43.21%